CCM® Therapy — My Approach to Identifying Patients
This recorded webinar will introduce CCM® therapy as an option for treating NYHA Stage III heart failure patients that remain symptomatic despite being on optimal medical treatment, that have an EF of 25 – 45%, and NOT receiving CRT. Meghan Emig, PA will provide an overview of the new CCM indications. Utilizing their personal experience, the faculty will describe one of their own case study experience with CCM and talk about their real-life patient responses to the therapy. Stephanie Toth, NP will discuss the screening process for eligible CCM patients from the EP perspective and provide a case study. David McCaskill, NP will provide his approach to identifying patients for CCM from a HF perspective and give examples of his clinical workflow.
Login to view comments.
Click here to Login
